These results strongly suggested that SRPK1 promotes EGFR-TKI resistance in NSCLC by escaping apoptosis during the initial treatment and subsequently, increasing receptor levels to accelerate progression. This evidence concerns the gene EGFR and non-small cell lung carcinoma.